EDGE PharmaTech
ActiveSummary
EDGE PharmaTech has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €7,813 and a net result of €62,813. Equity is shrinking by about 27% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 14% of 11,573 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
02-03
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
23-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
31-12
Financial
Weakest financial yearnet €36,189 ▼31.9%
Net result drops to €36,189, the lowest in the series; recovery starts the following year.
03-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Equity above €150,000equity €176,345 ▲43.1%
A profit in every financial year since 2021 builds equity to €176,345.
24-07
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial
Equity above €100,000equity €123,225 ▲45.3%
A profit in every financial year since 2021 builds equity to €123,225.
25-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.